论文部分内容阅读
随着我国医保制度全面实施、药品分类管理制度的进一步完善,药品零售市场还将进一步扩大,专家预计在未来五年以年均15％增长,到2005年可望达到600亿元,2020年我国将成为全球最大的OTC销售市场之一。国家药品监督管理局局长郑筱萸今年1月底表示,目前医药零售企业仅12万家,今后零售药店可以发展到30万家,缺口18万家。三九集团、重庆太极、华北制药、深圳万基、深圳海王、珠海丽珠、深圳一致、上海复星等制药企业和大量的外围资本开始涌
With the full implementation of China’s health insurance system and the further improvement of the drug classification management system, the pharmaceutical retail market will further expand. Experts expect to grow at an average annual rate of 15% in the next five years, and it is expected to reach 60 billion yuan by 2005. It will become one of the largest OTC sales markets in the world. Zheng Jun, director of the State Drug Administration, said at the end of January this year that there are currently only 120,000 pharmaceutical retail companies, and that the number of retail pharmacies in the future can reach 300,000 and the number of shortages is 180,000. Sanjiu Group, Chongqing Taiji, North China Pharmaceuticals, Shenzhen Wanji, Shenzhen Haiwang, Zhuhai Livzon, Shenzhen Unanimous, Shanghai Fosun and other pharmaceutical companies and a large number of peripheral capital began to surge